The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...
as well as Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia – both autologous cell therapies that seek to address the underlying genetic defect in SCD. Adakveo has, however ...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback